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Objective. To investigate intrathecal immune activation parameters and HIV-RNA in HIV-associated neurocognitive disorders
(HAND) of advanced naı¨ve HIV-infected patients and to evaluate their dynamics before and after initiation of antiretroviral
therapy (ART). Methods. Cross-sectional and longitudinal analysis of HIV RNA, proinflammatory cytokines (IL-6, IL-10, INF-
γ, TNF-α, TGF-β1, and TGF-β2) and chemokines (MIP-1α, MIP-1β, and MCP-1) in plasma and cerebrospinal fluid (CSF) of
HIV-infected patients with CD4 <200/μL. Results. HAND was diagnosed at baseline in 6/12 patients. Baseline CSF HIV-RNA
was comparable in patients with or without HAND, whereas CSF concentration of IL-6 and MIP-1β, proinflammatory cytokines,
was increased in HAND patients. CSF evaluation at 12 weeks was available in 10/12 cases. ART greatly reduced HIV-RNA in all
patients. Nevertheless, IL-6 and MIP-1β remained elevated after 12 weeks of therapy in HAND patients, in whom CSF HIV RNA
decay was slower than the plasmatic one as well. Conclusion. Immune activation, as indicated by inflammatory cytokines, but not
higher levels of HIV-RNA is observed in advanced naı¨ve HIV-infected patients with HAND. In HAND patients, ART introduction
resulted in a less rapid clearance of CSF viremia compared to plasma and no modifications of intratechal immune activation.
1. Introduction
HIV can cause a wide range of neurocognitive complications
which were recently regrouped under the acronym of HAND,
that is, HIV-associated neurocognitive disorders [1].
HAND reflects a spectrum of neurologic diseases ranging
from subclinical neuropsychological impairment, such as as-
ymptomatic neurocognitive impairment (ANI) or mild neu-
rocognitive disorder (MND), to clinically evident HIV-asso-
ciated dementia (HAD) [2]. Following the introduction of
antiretroviral therapy (ART), the HANDprofile has changed.
Indeed, widespread use of ART has decreased the prevalence
of HIV-associated dementia (HAD), but the prevalence of
milder forms of HIV-associated neurocognitive disorders
(HAND) has remained stable or increased among both treat-
ed and untreated individuals [3–5]. Prevalence of minor
cognitive deficits has increased as well and is currently
reported to be detectable in 20 to 50% of patients [6, 7].
The most probable explanation for this increase is that many
antiretroviral agents exhibit poor CSF and brain penetra-
tion [8]; additionally, these agents, may fail to completely
suppress HIV replication in the brain due to compartmental-
ization of HIV-1 infection within the central nervous system
(CNS).
HIV establishes an inflammatory response within the
CNS, resulting in macrophage activation. The inflammatory
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response is considered to be the main mediator of neu-
ronal damage in HIV-related neurodegenerative disease [9].
Despite eﬀective ART, a substantial proportion of patients
continue to show signs of macrophage/microglia activation
and intratechal immunoglobulin production in the CNS
[10].
The eﬀects of ART on CNS viral burden and CNS im-
mune activation need to be clarified in order to identify new
strategies for the prevention and treatment of neurocognitive
disorders.
In order to gain insight into these issues, we investigated
the potential relation between CSF HIV RNA level, immune
activation, and HAND in HIV-positive advanced naı¨ve pa-
tients before and after starting ART.
2. Material andMethods
2.1. Study Participants and Evaluations. Individuals were
enrolled at the Infectious Diseases Unit of San Gerardo Hos-
pital, University of Milan-Bicocca. Antiretroviral therapy-
naive subjects with CD4+ <200 cells/μL were eligible. Sub-
jects with current or past CNS infections, psychiatric dis-
eases, other chronic neurologic disorders, drugs or alcohol
abuse were excluded.Written informed consent was obtained
prior to enrolment.
At baseline and after 12 weeks of ART (zidovudine, lami-
vudine and lopinavir/ritonavir), patients underwent clini-
cal examination, virological and immunological assessment,
and CSF examination.
2.1.1. Neuropsychological Evaluation. Neuropsychological
evaluation was performed at baseline and at week 24. Neuro-
cognitive function was assessed by a neuropsychological
set of tests recommended by ACTG, designed to quantify
cognitive impairment. These tests cover diﬀerent cognitive
domains: trail-making A (speed of processing); trail-making
B (executive function); Mauri et al. test (Episodic memory);
Matrix test (visual and selective attention, speed, and
accuracy of visual searching); Wais-R vocabulary (language);
Montgomery-A˚sberg Depression Rating Scale (depressive
symptoms). Performance on each test was normalized for
age and education. ANI was defined as impairment in ≥2
cognitive domains that cannot be explained by opportunistic
CNS disease, systemic illness, psychiatric illness, substance
use disorders, or medications with CNS eﬀects [2]. MND
was defined as at least mild impairment (>1 SD below a
demographically appropriate normative mean), involving
≥2 cognitive domains that cannot be explained by con-
founding conditions and reported or demonstrated mild
functional decline that cannot be explained by confounding
conditions [2].
2.1.2. Laboratory Evaluation. HIV-RNA levels were mea-
sured in cell-free CSF and plasma using the PCR-Taqman
(lower limit of detection 40 copies/mL). Cytokines (IL-6, IL-
10, INF-γ, TNF-α, TGF-β1, TGF-β2) and chemokines (MIP-
1α, MIP-1β, MCP-1) concentrations were assessed by ELISA
(R&D System, Minneapolis, MN).
2.1.3. Statistical Methods. Descriptive results are presented
as medians with interquartile range (IQR). Chi-square or
Fisher’s exact test has been used to analyze categorical vari-
ables. ANOVA and Student’s t-test were used for continuous
variables unless they were abnormally distributed, in which
case the Kruskal-Wallis and Mann-Whitney U tests were
used.
All tests were two sided and a P value inferior to 0.05
was regarded as significant, although its meaning was merely
descriptive.
3. Results
3.1. Patients Characteristics. Six advanced naı¨ve HIV-infect-
ed patients with HAND (3 ANI and 3MND) and 6 advanced
naı¨ve HIV+ patients without HAND (controls) were enrolled
in the study (Table 1). Two patients were lost at followup
in the HAND group (1 ANI and 1 MND). Median baseline
CD4+ count was similar between the two groups: 88 cells/μL
(IQR 44–98) in HAND and 42 cells/μL (IQR 42–74) in
controls (P = 0.28). These values increased in both groups
after initiation of ART, reaching 188 cell/μL (IQR 178–205;
P = 0.009) in HAND and 175 cell/μL (IQ 123–394; P = 0.03)
in controls at week 12.
3.2. Plasmatic and CSF HIV-RNA Dynamics. Plasmatic HIV
RNA at baseline did not show statistically significant diﬀer-
ences between the two groups of patients (HAND:
4.53 log copies/mL (IQR4.22–5.55); controls: 5.30 log copies/
mL (IQR 5.18–5.55) (P = 0.24)). Twelve weeks after starting
ART, median HIV RNA in plasma was 2.32 log copies/mL
(IQR 1.85–2.48) in HAND patients and 1.59 log copies/mL
(IQR 1.59–1.72) in the control group. Median change
in plasma HIV-RNA level at the end of followup was
−3.07 log copies/mL (IQR −3.24–2.59) in HAND group and
−3.60 (IQR −3.39–3.20) in the control group (P = 0.06).
At baseline, median CSF HIV RNA was 3.61 log cop-
ies/mL (IQR 3.02–4.38) in the HAND group compared to
3.02 log copies/mL (IQR 3.39–4.64) in controls (P = 0.25).
After 12 weeks of ART, median CSF HIV RNA was
2.09log copies/mL in HAND group (IQR 1.59–2.08) and
1.59 log copies/mL (IQR 1.59–1.77) in the control group
(Figure 1(a)). At the end of followup, median change of
CSF HIV-RNA was −2.05 log copies/mL (IQR −2.76–1.08)
in HAND group and −1.67 (IQR −1.86–1.19) in control
group (P = 0.48).
We then calculated diﬀerence in HIV-RNA levels between
plasma and CSF (Δ), both at baseline visit and at week
12. A value >0.5 log copies/mL was observed in 3 out of 4
patients in the HAND group and in 1/5 in the control group,
reflecting a slower decrease in HIV-RNA level in CSF as
compared to plasma in HAND patients (Figure 1(b)).
3.3. CSF Inflammation Dynamics. At baseline, concentration
of inflammatory cytokines in CSF was diﬀerent between
the two groups of patients. Thus, MIP-1β was significantly
elevated in HAND patients (2.74 pg/mL, IQR 2.14–7.30)
compared to patients without HAND (1.44 pg/mL, IQR
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Table 1: Patients’ characteristics.
Baseline Week 24
Pt Age Sex
Ethnic
Grupa
CDC
NPS
Testb
CD4+
cell/μL
HIV-RNA
plasma
log10 cp/mL
HIV-RNA
CSF
log10 cp/mL
CSF WBC
cell/μL
CD4+
cell/μL
HIV-RNA
plasma
log10 cp/mL
HIV-RNA
CSF
log10 cp/mL
CSF WBC
cell/μL
1 40 M C C3 + 100 4.04 5.40 20 176 1.59 2.6 0
2 47 M I C3 +b 93 4.75 4.80 0 190 1.74 2.05 8
3 43 M C C3 +b 32 2.67 3.45 12 186 2.49 2.08 15
4 49 F C C3 +b 83 5.68 3.36 1 211 2.54
5 59 M C C3 + 102 5.75 4.14 1 317 2.46
6 27 M I C3 + 26 5.54 1.81 0 116 2.17 1.59 0
7 41 M C C3 − 42 5.87 3.26 0 234 1.76 1.59 0
8 36 M C B3 − 26 5.62 2.62 1 49 1.59 1.59 1
9 25 M A C3 − 172 5.16 4.16 0 145 1.59 1.59 0
10 25 F I B3 − 106 4.18 3.69 8 474 1.59 1.83 1
11 37 M C C3 − 148 5.36 2.63 0 448 2.27 2.16 0
12 53 M C C3 − 43 5.23 2.78 0 116 1.59 1.59 11
a
: C: Caucasian, A: African, and I: Ispanic.
b: MND, +: altered NPS test.
Table 2: CSF inflammation markers dynamics.
CSF concentration (pg/mL) HAND group Controls P
IL-6 BL 3.50 (2.96–6.22) 0.31 (0.18–1.04) 0.06
IL-6 W12 6.00 (2.25–5.75) 1.00 (0.00–1.52) 0.06
TGF-β1 BL 0.11 (0.00–11.75) 12.40 (0.00–24.10) ns
TGF-β1 W12 0.10 (0.00–5.20) 13.50 (9.25–16.75) ns
TGF-β2 BL 59.00 (0.00–87.20) 99.12 (20.10–147.00) ns
TGF-β2 W12 46.11 (41.72–61.11) 79.06 (69.13–92.23) ns
MIP-1α BL 0.70 (0.00–2.86) 0.10 (0.00–0.12) 0.05
MIP-1αW12 1.00 (1.00–6.50) 0.10 (0.00–0.22) 0.05
MIP-1β BL 2.74 (2.14–7.30) 1.44 (0.94–2.13) 0.03
MIP-1β W12 2.65 (1.42–1.87) 1.61 (0.48–1.87) 0.05
MCP-1 log10 BL 2.85 (2.84–3.06) 2.69 (2.65–2.75) 0.06
MCP-1 log10 W12 2.63 (2.61–2.79) 2.64 (2.61–2.68) ns
0.94–2.13) (P = 0.03) (Figure 1(c)). Similarly, IL-6 CSF
concentration was higher (3.5 pg/mL, IQR 2.96–6.22) in
HAND patients compared to the control group (0.313 pg/mL
IQR 0.18–1.04) (P = 0.06) (Figure 1(c)).
After 3 months of ART, no significant changes in cyto-
kines and chemokines levels were observed in either group
of patients despite a significant reduction in CSF HIV repli-
cation,. In particular, HAND patients did not show changes
in the CSF concentration of either MIP-1β (2.65 pg/mL, IQR
1.42–1.87) or IL-6 (6 pg/mL, IQR 2.25–5.75) and concen-
trations of these cytokines thus remained significantly higher
than controls.
CSF concentration of cytokines is chemokines are rep-
resented in Table 2. IL-10 and TNF-α CSF concentrations
were undetectable in all patients at baseline and followup;
INF-γ CSF concentration was detectable in 2/6 patients
with HAND at baseline and 1/4 patients with HAND at
week 12 (undetectable levels were found in controls at both
timepoints).
4. Discussion
Data herein show that intrathecal immune activation plays
a significant role in neuropathogenesis of cognitive impair-
ment during HIV infection, as demonstrated in naı¨ve pa-
tients with advanced immune suppression.
Typically, magnitude of CSF infection varies among pa-
tients. It does, however, correlate strongly with intratechal
inflammation and development of HIV-associated dementia
[9]. In our cohort of naı¨ve HIV-infected patients with ad-
vanced disease, levels of HIV-RNA in blood and CSF of
patients with HAND were comparable to those of patients
without HAND. Interestingly, however, in HAND patients,
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Figure 1: Representation of CSF HIV-RNA dynamics (a), diﬀerence in HIV-RNA levels between plasma and CSF (Δ) (b) and cytokines
(IL-6, MIP-1β) concentrations at baseline. At baseline and after 12 weeks of ART, CSF HIV-RNA was not diﬀerent between HAND patients
and controls (Figure 1(a)). Diﬀerence in HIV-RNA levels between plasma and CSF (Δ), both at baseline and at week 12, showed a value >
0.5 log copies/mL in 3/4 patients in the HAND group and in 1/5 in the control group, reflecting a slower decrease in HIV-RNA level in CSF as
compared to plasma in HAND patients (Figure 1(b)). At baseline concentration of MIP-1b and IL-6 in CSF, there was a diﬀerence between
the two groups of patients (Figure 1(c)).
we did observe a slower decay of CSF HIV replication as
compared to plasma, indicating a more persistent replication
of the virus in the CNS compartment. This suggests a mod-
el in which the presence of HAND is associated with com-
partmentalization of virus replication [7].
CNS immune activation accompanies HIV infection and
is an important mediator of neurological injury. The specific
mechanism(s) by which inflammatory cells are recruited into
the CNS revolves around peripheral immune activation and
a chemokine gradient established within the CNS as a result
of viral infection and glial immune activation. In HAND pa-
tients, we found higher levels of macrophages-produced in-
flammatory cytokines, confirming the significant role of CNS
macrophage activation in inducing the neurologic damage.
Currently, many unanswered questions remain regarding
the relationship between neuroinflammation, blood-brain
barrier (BBB) dysfunction, and progressive HIV-1 infection
and how these factors aﬀect the onset and development of
HAND. The higher levels of IL-6 observed in our HAND
patients confirm its specific role as mediator of neuroinflam-
mation during chronic HIV inflammation. Recently, several
studies identified possible pathways involved in the induction
or generation of IL-6 from brain microvascular endothelial
cells, as well as astrocytes [11, 12].
Moreover, higher levels of MIP-1β detected in the CSF
of HIV-infected patients with HAND confirm previous
observations of upregulation of this chemokine production
in the brain of patients with ADC [13].
Similarly to what is observed for HIV-RNA levels, inflam-
mation, as measured by CSF pleocytosis, decreases during
ART-reduced CSF inflammatory response in the context of
ART being suggested to be secondary to reduction of either
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local antigen stimulus or of HIV-related chemotaxis. In-
terestingly, in our advanced naı¨ve HIV-infected HAND pa-
tients, intrathecal immune activation parameters, as mea-
sured by inflammatory cytokines is not influenced by ART
initiation. This supports the hypothesis that intrathecal
inflammation and immunoactivation play a critical role in
patients with severe immune depression, associated with
more frequent compartimentalization of HIV infection.
Moreover, our observation confirms previous studies de-
scribing the persistence of CNS immune activation even in
presence of virologically eﬀective ART.
In our sample of advanced naı¨ve HAND patients, the
profile of CSF HIV infection was characterized by the
presence of intratechal immune activation, as stated by the
higher levels of inflammatory cytokines, accompanied by less
rapid clearance of CSF viremia compared to plasma after
the introduction of ART. Long-term observation focusing on
neurological outcomes should provide further insight into
the neurological prognosis of these patients.
Acknowledgments
The present study was funded by a grant from “Ermenegildo
Zegna” Foundation, Italy, and AHSI Company, Milan, Italy.
These data were presented in part at the 16th Conference
on Retroviruses and Opportunistic Infections, February 8-
11, 2009, Montreal, Canada.
References
[1] N. Sacktor, P. M. Tarwater, R. L. Skolasky et al., “CSF
antiretroviral drug penetrance and the treatment of HIV-
associated psychomotor slowing,”Neurology, vol. 57, no. 3, pp.
542–544, 2001.
[2] A. Antinori, G. Arendt, J. T. Becker et al., “Updated research
nosology for HIV-associated neurocognitive disorders,” Neu-
rology, vol. 69, no. 18, pp. 1789–1799, 2007.
[3] J. C. McArthur, J. Steiner, N. Sacktor, and A. Nath, “Human
immunodeficiency virus-associated neurocognitive disorders
mind the gap,” Annals of Neurology, vol. 67, no. 6, pp. 699–714,
2010.
[4] K. Bhaskaran, C. Mussini, A. Antinori et al., “Changes in the
incidence and predictors of human immunodeficiency virus-
associated dementia in the era of highly active antiretroviral
therapy,”Annals of Neurology, vol. 63, no. 2, pp. 213–221, 2008.
[5] N. Sacktor, “The epidemiology of human immunodeficiency
virus-associated neurological disease in the era of highly active
antiretroviral therapy,” Journal of NeuroVirology, vol. 8, no. 2,
pp. 115–121, 2002.
[6] R. K. Heaton, D. R. Franklin, R. J. Ellis et al., “HIV-
associated neurocognitive disorders before and during the era
of combination antiretroviral therapy: diﬀerences in rates,
nature, and predictors,” Journal of NeuroVirology, vol. 17, no.
1, pp. 3–16, 2011.
[7] S. Simioni, M. Cavassini, J. M. Annoni et al., “Cognitive dys-
function in HIV patients despite long-standing suppression of
viremia,” AIDS, vol. 24, no. 9, pp. 1243–1250, 2010.
[8] S. Letendre, J. Marquie-Beck, E. Capparelli et al., “Validation
of the CNS penetration-eﬀectiveness rank for quantifying
antiretroviral penetration into the central nervous system,”
Archives of Neurology, vol. 65, no. 1, pp. 65–70, 2008.
[9] F. Gonza´lez-Scarano and J. Martı´n-Garcı´a, “The neuropatho-
genesis of AIDS,” Nature Reviews Immunology, vol. 5, no. 1,
pp. 69–81, 2005.
[10] A. Ede´n, R. W. Price, S. Spudich, D. Fuchs, L. Hagberg,
and M. Gissle´n, “Immune activation of the central nervous
system is still present after >4 years of eﬀective highly active
antiretroviral therapy,” Journal of Infectious Diseases, vol. 196,
no. 12, pp. 1779–1783, 2007.
[11] A. Shah, A. S. Verma, K. H. Patel et al., “HIV-1 gp120
Induces expression of IL-6 through a nuclear factor-Kappa B-
dependent mechanism: suppression by gp120 specific small
interfering RNA,” PLoS One, vol. 6, no. 6, Article ID e21261,
2011.
[12] A. Chaudhuri, B. Yang, H. E. Gendelman, Y. Persidsky, and
G. D. Kanmogne, “STAT1 signaling modulates HIV-1-induced
inflammatory responses and leukocyte transmigration across
the blood-brain barrier,” Blood, vol. 111, no. 4, pp. 2062–2072,
2008.
[13] B. Canque, M. Rosenzwajg, A. Gey, E. Tartour, W. H. Fridman,
and J. C. Gluckman, “Macrophage inflammatory protein-1α
is induced by human immunodeficiency virus infection of
monocyte-derived macrophages,” Blood, vol. 87, no. 5, pp.
2011–2019, 1996.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
